Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

NCT06125197 is registered in ClinicalTrials.gov with TILT Biotherapeutics Ltd. as lead sponsor.

NCT NCT06125197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06125197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
Lead sponsor
TILT Biotherapeutics Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 23, 2024
Completion date
May 30, 2026
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer